Epigenetics in non-alcoholic fatty liver disease

Molecular Aspects of Medicine

Volumn 54, Issue , 2017, Pages 78-88

  Lee, Jooho ^a   Kim, Yuri ^b   Friso, Simonetta ^c   Choi, Sang Woon ^a  

^a CHA University   (South Korea)

^b Ewha Womans University   (South Korea)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

DNA methylation; Epigenetics; Histone modifications; microRNA; Non alcoholic fatty liver disease (NAFLD); Non alcoholic steatohepatitis (NASH)

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 10B; MICRORNA 122; MICRORNA 155; MICRORNA 16; MICRORNA 181; MICRORNA 21; MICRORNA 33A; MICRORNA 33B; MICRORNA 34A; MICRORNA 451; SIRTUIN 1; SIRTUIN 3; UNCLASSIFIED DRUG; HISTONE;

CARBON METABOLISM; DISEASE COURSE; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; LIVER CELL CARCINOMA; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; REVIEW; ANIMAL; GENETIC EPIGENESIS; GENETICS; METABOLISM; PROTEIN PROCESSING;

ANIMALS; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 85007294669     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2016.11.008     Document Type: Review

References (140)

1. Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., Angulo, P., The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129:1 (2005), 113–121.
2. Adams, L.A., Sanderson, S., Lindor, K.D., Angulo, P., The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42:1 (2005), 132–138.
3. Afonso, M.B., Rodrigues, P.M., Simao, A.L., Castro, R.E., Circulating microRNAs as potential biomarkers in non-alcoholic fatty liver disease and hepatocellular carcinoma. J. Clin. Med., 5(3), 2016.
4. Ambros, V., microRNAs: tiny regulators with great potential. Cell 107:7 (2001), 823–826.
5. Anstee, Q.M., Day, C.P., The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 10:11 (2013), 645–655.
6. Anstee, Q.M., Targher, G., Day, C.P., Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10:6 (2013), 330–344.
7. Arrese, M., Eguchi, A., Feldstein, A.E., Circulating microRNAs: emerging biomarkers of liver disease. Semin. Liver Dis. 35:1 (2015), 43–54.
8. Baffy, G., MicroRNAs in nonalcoholic fatty liver disease. J. Clin. Med. 4:12 (2015), 1977–1988.
9. Bao, J., Scott, I., Lu, Z., Pang, L., Dimond, C.C., Gius, D., Sack, M.N., SIRT3 is regulated by nutrient excess and modulates hepatic susceptibility to lipotoxicity. Free Radic. Biol. Med. 49:7 (2010), 1230–1237.
10. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:2 (2004), 281–297.
11. Baselga-Escudero, L., Pascual-Serrano, A., Ribas-Latre, A., Casanova, E., Salvado, M.J., Arola, L., Arola-Arnal, A., Blade, C., Long-term supplementation with a low dose of proanthocyanidins normalized liver miR-33a and miR-122 levels in high-fat diet-induced obese rats. Nutr. Res. 35:4 (2015), 337–345.
12. Bellentani, S., Scaglioni, F., Marino, M., Bedogni, G., Epidemiology of non-alcoholic fatty liver disease. Dig. Dis. 28:1 (2010), 155–161.
13. Blander, G., Guarente, L., The Sir2 family of protein deacetylases. Annu. Rev. Biochem. 73 (2004), 417–435.
14. Bricambert, J., Miranda, J., Benhamed, F., Girard, J., Postic, C., Dentin, R., Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J. Clin. Investig. 120:12 (2010), 4316–4331.
15. Brockhausen, J., Tay, S.S., Grzelak, C.A., Bertolino, P., Bowen, D.G., d'Avigdor, W.M., Teoh, N., Pok, S., Shackel, N., Gamble, J.R., Vadas, M., McCaughan, G.W., miR-181a mediates TGF-beta-induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int. 35:1 (2015), 240–253.
16. Budhu, A., Jia, H.L., Forgues, M., Liu, C.G., Goldstein, D., Lam, A., Zanetti, K.A., Ye, Q.H., Qin, L.X., Croce, C.M., Tang, Z.Y., Wang, X.W., Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47:3 (2008), 897–907.
17. Callegari, E., Elamin, B.K., Giannone, F., Milazzo, M., Altavilla, G., Fornari, F., Giacomelli, L., D'Abundo, L., Ferracin, M., Bassi, C., Zagatti, B., Corra, F., Miotto, E., Lupini, L., Bolondi, L., Gramantieri, L., Croce, C.M., Sabbioni, S., Negrini, M., Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model. Hepatology 56:3 (2012), 1025–1033.
18. Carabelli, J., Burgueno, A.L., Rosselli, M.S., Gianotti, T.F., Lago, N.R., Pirola, C.J., Sookoian, S., High fat diet-induced liver steatosis promotes an increase in liver mitochondrial biogenesis in response to hypoxia. J. Cell Mol. Med. 15:6 (2011), 1329–1338.
19. Castro, R.E., Ferreira, D.M., Afonso, M.B., Borralho, P.M., Machado, M.V., Cortez-Pinto, H., Rodrigues, C.M., miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J. Hepatol. 58:1 (2013), 119–125.
20. Celikbilek, M., Baskol, M., Taheri, S., Deniz, K., Dogan, S., Zararsiz, G., Gursoy, S., Guven, K., Ozbakir, O., Dundar, M., Yucesoy, M., Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J. Hepatol. 6:8 (2014), 613–620.
21. Cermelli, S., Ruggieri, A., Marrero, J.A., Ioannou, G.N., Beretta, L., Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One, 6(8), 2011, e23937.
22. Chan, H.M., La Thangue, N.B., p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114:Pt 13 (2001), 2363–2373.
23. Chang, X., Yan, H., Fei, J., Jiang, M., Zhu, H., Lu, D., Gao, X., Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats. J. Lipid Res. 51:9 (2010), 2504–2515.
24. Chen, Z.J., Pikaard, C.S., Epigenetic silencing of RNA polymerase I transcription: a role for DNA methylation and histone modification in nucleolar dominance. Genes Dev. 11:16 (1997), 2124–2136.
25. Cheung, O., Puri, P., Eicken, C., Contos, M.J., Mirshahi, F., Maher, J.W., Kellum, J.M., Min, H., Luketic, V.A., Sanyal, A.J., Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48:6 (2008), 1810–1820.
26. Chew, T.W., Jiang, X., Yan, J., Wang, W., Lusa, A.L., Carrier, B.J., West, A.A., Malysheva, O.V., Brenna, J.T., Gregory, J.F. 3rd, Caudill, M.A., Folate intake, MTHFR genotype, and sex modulate choline metabolism in mice. J. Nutr. 141:8 (2011), 1475–1481.
27. Choi, S.W., Friso, S., Epigenetics: a new bridge between nutrition and health. Adv. Nutr. 1:1 (2010), 8–16.
28. Colak, Y., Yesil, A., Mutlu, H.H., Caklili, O.T., Ulasoglu, C., Senates, E., Takir, M., Kostek, O., Yilmaz, Y., Yilmaz Enc, F., Tasan, G., Tuncer, I., A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J. Gastrointestin Liver Dis. 23:3 (2014), 311–319.
29. Cordero, P., Campion, J., Milagro, F.I., Martinez, J.A., Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: effect of dietary methyl donor supplementation. Mol. Genet. Metab. 110:3 (2013), 388–395.
30. Cortez, M.A., Bueso-Ramos, C., Ferdin, J., Lopez-Berestein, G., Sood, A.K., Calin, G.A., MicroRNAs in body fluids–the mix of hormones and biomarkers. Nat. Rev. Clin. Oncol. 8:8 (2011), 467–477.
31. Csak, T., Bala, S., Lippai, D., Satishchandran, A., Catalano, D., Kodys, K., Szabo, G., microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis. Liver Int. 35:2 (2015), 532–541.
32. da Silva, R.P., Kelly, K.B., Al Rajabi, A., Jacobs, R.L., Novel insights on interactions between folate and lipid metabolism. Biofactors 40:3 (2014), 277–283.
33. Dattaroy, D., Pourhoseini, S., Das, S., Alhasson, F., Seth, R.K., Nagarkatti, M., Michelotti, G.A., Diehl, A.M., Chatterjee, S., Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 308:4 (2015), G298–G312.
34. Davalos, A., Goedeke, L., Smibert, P., Ramirez, C.M., Warrier, N.P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J.C., Esplugues, E., Fisher, E.A., Penalva, L.O., Moore, K.J., Suarez, Y., Lai, E.C., Fernandez-Hernando, C., miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc. Natl. Acad. Sci. U. S. A. 108:22 (2011), 9232–9237.
35. Day, C.P., James, O.F., Steatohepatitis: a tale of two “hits”?. Gastroenterology 114:4 (1998), 842–845.
36. Denechaud, P.D., Dentin, R., Girard, J., Postic, C., Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett. 582:1 (2008), 68–73.
37. Derdak, Z., Villegas, K.A., Harb, R., Wu, A.M., Sousa, A., Wands, J.R., Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J. Hepatol. 58:4 (2013), 785–791.
38. Ding, J., Li, M., Wan, X., Jin, X., Chen, S., Yu, C., Li, Y., Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci. Rep., 5, 2015, 13729.
39. Ekstedt, M., Franzen, L.E., Mathiesen, U.L., Thorelius, L., Holmqvist, M., Bodemar, G., Kechagias, S., Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44:4 (2006), 865–873.
40. Esau, C., Davis, S., Murray, S.F., Yu, X.X., Pandey, S.K., Pear, M., Watts, L., Booten, S.L., Graham, M., McKay, R., Subramaniam, A., Propp, S., Lollo, B.A., Freier, S., Bennett, C.F., Bhanot, S., Monia, B.P., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3:2 (2006), 87–98.
41. Estep, M., Armistead, D., Hossain, N., Elarainy, H., Goodman, Z., Baranova, A., Chandhoke, V., Younossi, Z.M., Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 32:3 (2010), 487–497.
42. Fassio, E., Alvarez, E., Dominguez, N., Landeira, G., Longo, C., Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40:4 (2004), 820–826.
43. Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S.E., Alenghat, T., Liu, X.S., Lazar, M.A., A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 331:6022 (2011), 1315–1319.
44. Fernandez-Hernando, C., Suarez, Y., Rayner, K.J., Moore, K.J., MicroRNAs in lipid metabolism. Curr. Opin. Lipidol. 22:2 (2011), 86–92.
45. Ferreira, D.M., Simao, A.L., Rodrigues, C.M., Castro, R.E., Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease. FEBS J. 281:11 (2014), 2503–2524.
46. Friedman, R.C., Farh, K.K., Burge, C.B., Bartel, D.P., Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19:1 (2009), 92–105.
47. Gallego-Duran, R., Romero-Gomez, M., Epigenetic mechanisms in non-alcoholic fatty liver disease: an emerging field. World J. Hepatol. 7:24 (2015), 2497–2502.
48. Ge, W., Yu, D.C., Li, Q.G., Chen, X., Zhang, C.Y., Ding, Y.T., Expression of serum miR-16, let-7f, and miR-21 in patients with hepatocellular carcinoma and their clinical significances. Clin. Lab. 60:3 (2014), 427–434.
49. Gibbs, J.R., van der Brug, M.P., Hernandez, D.G., Traynor, B.J., Nalls, M.A., Lai, S.-L., Arepalli, S., Dillman, A., Rafferty, I.P., Troncoso, J., Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. PLoS Genet., 6(5), 2010, e1000952.
50. Gori, M., Arciello, M., Balsano, C., MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed. Res. Int., 2014, 2014, 741465.
51. Gramantieri, L., Ferracin, M., Fornari, F., Veronese, A., Sabbioni, S., Liu, C.G., Calin, G.A., Giovannini, C., Ferrazzi, E., Grazi, G.L., Croce, C.M., Bolondi, L., Negrini, M., Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res. 67:13 (2007), 6092–6099.
52. Granger, A., Abdullah, I., Huebner, F., Stout, A., Wang, T., Huebner, T., Epstein, J.A., Gruber, P.J., Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 22:10 (2008), 3549–3560.
53. Guo, C.J., Pan, Q., Li, D.G., Sun, H., Liu, B.W., miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: an essential role for apoptosis. J. Hepatol. 50:4 (2009), 766–778.
54. Ha, M., Kim, V.N., Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15:8 (2014), 509–524.
55. Herranz, D., Munoz-Martin, M., Canamero, M., Mulero, F., Martinez-Pastor, B., Fernandez-Capetillo, O., Serrano, M., Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun., 1, 2010, 3.
56. Herranz, D., Serrano, M., SIRT1: recent lessons from mouse models. Nat. Rev. Cancer 10:12 (2010), 819–823.
57. Hirschey, M.D., Shimazu, T., Capra, J.A., Pollard, K.S., Verdin, E., SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2. Aging (Albany NY) 3:6 (2011), 635–642.
58. Hirschey, M.D., Shimazu, T., Jing, E., Grueter, C.A., Collins, A.M., Aouizerat, B., Stancakova, A., Goetzman, E., Lam, M.M., Schwer, B., Stevens, R.D., Muehlbauer, M.J., Kakar, S., Bass, N.M., Kuusisto, J., Laakso, M., Alt, F.W., Newgard, C.B., Farese, R.V. Jr., Kahn, C.R., Verdin, E., SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 44:2 (2011), 177–190.
59. Hochberg, Z., Feil, R., Constancia, M., Fraga, M., Junien, C., Carel, J.C., Boileau, P., Le Bouc, Y., Deal, C.L., Lillycrop, K., Scharfmann, R., Sheppard, A., Skinner, M., Szyf, M., Waterland, R.A., Waxman, D.J., Whitelaw, E., Ong, K., Albertsson-Wikland, K., Child health, developmental plasticity, and epigenetic programming. Endocr. Rev. 32:2 (2011), 159–224.
60. Hur, W., Lee, J.H., Kim, S.W., Kim, J.H., Bae, S.H., Kim, M., Hwang, D., Kim, Y.S., Park, T., Um, S.J., Song, B.J., Yoon, S.K., Downregulation of microRNA-451 in non-alcoholic steatohepatitis inhibits fatty acid-induced proinflammatory cytokine production through the AMPK/AKT pathway. Int. J. Biochem. Cell Biol. 64 (2015), 265–276.
61. Jacobs, R.L., Lingrell, S., Zhao, Y., Francis, G.A., Vance, D.E., Hepatic CTP: phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J. Biol. Chem. 283:4 (2008), 2147–2155.
62. Jiang, L., Cheng, Q., Zhang, B.H., Zhang, M.Z., Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: a validation set from China. Med. Baltim., 94(10), 2015, e603.
63. Jin, X., Ye, Y.F., Chen, S.H., Yu, C.H., Liu, J., Li, Y.M., MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig. Liver Dis. 41:4 (2009), 289–297.
64. Kantartzis, K., Schick, F., Haring, H.U., Stefan, N., Environmental and genetic determinants of fatty liver in humans. Dig. Dis. 28:1 (2010), 169–178.
65. Kim, H.S., Patel, K., Muldoon-Jacobs, K., Bisht, K.S., Aykin-Burns, N., Pennington, J.D., van der Meer, R., Nguyen, P., Savage, J., Owens, K.M., Vassilopoulos, A., Ozden, O., Park, S.H., Singh, K.K., Abdulkadir, S.A., Spitz, D.R., Deng, C.X., Gius, D., SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 17:1 (2010), 41–52.
66. Kim, N.H., Kim, H.S., Li, X.Y., Lee, I., Choi, H.S., Kang, S.E., Cha, S.Y., Ryu, J.K., Yoon, D., Fearon, E.R., Rowe, R.G., Lee, S., Maher, C.A., Weiss, S.J., Yook, J.I., A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J. Cell Biol. 195:3 (2011), 417–433.
67. Klose, R.J., Bird, A.P., Genomic DNA methylation: the mark and its mediators. Trends Biochem. Sci. 31:2 (2006), 89–97.
68. Kong, L., Zhu, J., Han, W., Jiang, X., Xu, M., Zhao, Y., Dong, Q., Pang, Z., Guan, Q., Gao, L., Zhao, J., Zhao, L., Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 48:1 (2011), 61–69.
69. Korean Association for the Study of the, L., KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 19:4 (2013), 325–348.
70. Kotronen, A., Westerbacka, J., Bergholm, R., Pietilainen, K.H., Yki-Jarvinen, H., Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92:9 (2007), 3490–3497.
71. Krutzfeldt, J., Rajewsky, N., Braich, R., Rajeev, K.G., Tuschl, T., Manoharan, M., Stoffel, M., Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:7068 (2005), 685–689.
72. Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S.T., Ghoshal, K., Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J. Cell Biochem. 99:3 (2006), 671–678.
73. Lee, J.H., Friso, S., Choi, S.W., Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition. Nutrients 6:8 (2014), 3303–3325.
74. Lewis, A.P., Jopling, C.L., Regulation and biological function of the liver-specific miR-122. Biochem. Soc. Trans. 38:6 (2010), 1553–1557.
75. Li, J., Ghazwani, M., Zhang, Y., Lu, J., Li, J., Fan, J., Gandhi, C.R., Li, S., miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression. J. Hepatol. 58:3 (2013), 522–528.
76. Li, Y.Y., Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J. Gastroenterol. 18:45 (2012), 6546–6551.
77. Li, Z.J., Ou-Yang, P.H., Han, X.P., Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells. Cell Signal 26:1 (2014), 141–148.
78. Liao, C.G., Kong, L.M., Zhou, P., Yang, X.L., Huang, J.G., Zhang, H.L., Lu, N., miR-10b is overexpressed in hepatocellular carcinoma and promotes cell proliferation, migration and invasion through RhoC, uPAR and MMPs. J. Transl. Med., 12, 2014, 234.
79. Lin, X., Jia, J., Du, T., Li, W., Wang, X., Wei, J., Lin, X., Zeng, H., Yao, L., Chen, X., Zhuang, J., Weng, J., Liu, Y., Lin, J., Wu, Q., Wang, W., Yao, K., Xu, K., Xiao, D., Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism. PLoS One, 10(3), 2015, e0118417.
80. Ling, C., Groop, L., Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58:12 (2009), 2718–2725.
81. Loyer, X., Paradis, V., Henique, C., Vion, A.C., Colnot, N., Guerin, C.L., Devue, C., On, S., Scetbun, J., Romain, M., Paul, J.L., Rothenberg, M.E., Marcellin, P., Durand, F., Bedossa, P., Prip-Buus, C., Bauge, E., Staels, B., Boulanger, C.M., Tedgui, A., Rautou, P.E., Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut 65:11 (2016), 1882–1894.
82. Lu, S.C., Alvarez, L., Huang, Z.Z., Chen, L., An, W., Corrales, F.J., Avila, M.A., Kanel, G., Mato, J.M., Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation. Proc. Natl. Acad. Sci. U. S. A. 98:10 (2001), 5560–5565.
83. Lu, S.C., Mato, J.M., S-adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92:4 (2012), 1515–1542.
84. Martinez-Chantar, M.L., Corrales, F.J., Martinez-Cruz, L.A., Garcia-Trevijano, E.R., Huang, Z.Z., Chen, L., Kanel, G., Avila, M.A., Mato, J.M., Lu, S.C., Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A. FASEB J. 16:10 (2002), 1292–1294.
85. Masarone, M., Federico, A., Abenavoli, L., Loguercio, C., Persico, M., Non alcoholic fatty liver: epidemiology and natural history. Rev. Recent Clin. Trials 9:3 (2014), 126–133.
86. Mato, J.M., Lu, S.C., Role of S-adenosyl-L-methionine in liver health and injury. Hepatology 45:5 (2007), 1306–1312.
87. Mazzoccoli, G., Vinciguerra, M., Oben, J., Tarquini, R., De Cosmo, S., Non-alcoholic fatty liver disease: the role of nuclear receptors and circadian rhythmicity. Liver Int. 34:8 (2014), 1133–1152.
88. McCullough, A.J., The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 8:3 (2004), 521–533 (viii).
89. Meng, F., Henson, R., Wehbe-Janek, H., Ghoshal, K., Jacob, S.T., Patel, T., MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:2 (2007), 647–658.
90. Merlo, A., Herman, J.G., Mao, L., Lee, D.J., Gabrielson, E., Burger, P.C., Baylin, S.B., Sidransky, D., 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1:7 (1995), 686–692.
91. Miao, F., Gonzalo, I.G., Lanting, L., Natarajan, R., In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J. Biol. Chem. 279:17 (2004), 18091–18097.
92. Mitchell, P.S., Parkin, R.K., Kroh, E.M., Fritz, B.R., Wyman, S.K., Pogosova-Agadjanyan, E.L., Peterson, A., Noteboom, J., O'Briant, K.C., Allen, A., Lin, D.W., Urban, N., Drescher, C.W., Knudsen, B.S., Stirewalt, D.L., Gentleman, R., Vessella, R.L., Nelson, P.S., Martin, D.B., Tewari, M., Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. U. S. A. 105:30 (2008), 10513–10518.
93. Miyaaki, H., Ichikawa, T., Kamo, Y., Taura, N., Honda, T., Shibata, H., Milazzo, M., Fornari, F., Gramantieri, L., Bolondi, L., Nakao, K., Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 34:7 (2014), e302–307.
94. Mohr, A.M., Mott, J.L., Overview of microRNA biology. Semin. Liver Dis. 35:1 (2015), 3–11.
95. Murphy, S.K., Yang, H., Moylan, C.A., Pang, H., Dellinger, A., Abdelmalek, M.F., Garrett, M.E., Ashley-Koch, A., Suzuki, A., Tillmann, H.L., Hauser, M.A., Diehl, A.M., Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease. Gastroenterology 145:5 (2013), 1076–1087.
96. Oberdoerffer, P., Michan, S., McVay, M., Mostoslavsky, R., Vann, J., Park, S.K., Hartlerode, A., Stegmuller, J., Hafner, A., Loerch, P., Wright, S.M., Mills, K.D., Bonni, A., Yankner, B.A., Scully, R., Prolla, T.A., Alt, F.W., Sinclair, D.A., SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 135:5 (2008), 907–918.
97. Ogawa, T., Enomoto, M., Fujii, H., Sekiya, Y., Yoshizato, K., Ikeda, K., Kawada, N., MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 61:11 (2012), 1600–1609.
98. Palacios, J.A., Herranz, D., De Bonis, M.L., Velasco, S., Serrano, M., Blasco, M.A., SIRT1 contributes to telomere maintenance and augments global homologous recombination. J. Cell Biol. 191:7 (2010), 1299–1313.
99. Panera, N., Gnani, D., Crudele, A., Ceccarelli, S., Nobili, V., Alisi, A., MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World J. Gastroenterol. 20:41 (2014), 15079–15086.
100. Park, L.K., Friso, S., Choi, S.W., Nutritional influences on epigenetics and age-related disease. Proc. Nutr. Soc. 71:1 (2012), 75–83.
101. Pazienza, V., Borghesan, M., Mazza, T., Sheedfar, F., Panebianco, C., Williams, R., Mazzoccoli, G., Andriulli, A., Nakanishi, T., Vinciguerra, M., SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation. Aging (Albany NY) 6:1 (2014), 35–47.
102. Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., Mazzaferro, V., Lowe, S.W., Croce, C.M., Dejean, A., miR-221 overexpression contributes to liver tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 107:1 (2010), 264–269.
103. Pirola, C.J., Fernandez Gianotti, T., Castano, G.O., Mallardi, P., San Martino, J., Mora Gonzalez Lopez Ledesma, M., Flichman, D., Mirshahi, F., Sanyal, A.J., Sookoian, S., Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64:5 (2015), 800–812.
104. Pirola, C.J., Gianotti, T.F., Burgueno, A.L., Rey-Funes, M., Loidl, C.F., Mallardi, P., Martino, J.S., Castano, G.O., Sookoian, S., Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 62:9 (2013), 1356–1363.
105. Podrini, C., Borghesan, M., Greco, A., Pazienza, V., Mazzoccoli, G., Vinciguerra, M., Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD). Curr. Pharm. Des. 19:15 (2013), 2737–2746.
106. Pogribny, I.P., Tryndyak, V.P., Bagnyukova, T.V., Melnyk, S., Montgomery, B., Ross, S.A., Latendresse, J.R., Rusyn, I., Beland, F.A., Hepatic epigenetic phenotype predetermines individual susceptibility to hepatic steatosis in mice fed a lipogenic methyl-deficient diet. J. Hepatol. 51:1 (2009), 176–186.
107. Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., Li, X., Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 9:4 (2009), 327–338.
108. Qu, K.Z., Zhang, K., Li, H., Afdhal, N.H., Albitar, M., Circulating microRNAs as biomarkers for hepatocellular carcinoma. J. Clin. Gastroenterol. 45:4 (2011), 355–360.
109. Rafiq, N., Bai, C., Fang, Y., Srishord, M., McCullough, A., Gramlich, T., Younossi, Z.M., Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7:2 (2009), 234–238.
110. Rayner, K.J., Esau, C.C., Hussain, F.N., McDaniel, A.L., Marshall, S.M., van Gils, J.M., Ray, T.D., Sheedy, F.J., Goedeke, L., Liu, X., Khatsenko, O.G., Kaimal, V., Lees, C.J., Fernandez-Hernando, C., Fisher, E.A., Temel, R.E., Moore, K.J., Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478:7369 (2011), 404–407.
111. Rottiers, V., Najafi-Shoushtari, S.H., Kristo, F., Gurumurthy, S., Zhong, L., Li, Y., Cohen, D.E., Gerszten, R.E., Bardeesy, N., Mostoslavsky, R., Naar, A.M., MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb. Symp. Quant. Biol. 76 (2011), 225–233.
112. Schwer, B., Verdin, E., Conserved metabolic regulatory functions of sirtuins. Cell Metab. 7:2 (2008), 104–112.
113. Serviddio, G., Giudetti, A.M., Bellanti, F., Priore, P., Rollo, T., Tamborra, R., Siculella, L., Vendemiale, G., Altomare, E., Gnoni, G.V., Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PloS One, 6(9), 2011, e24084.
114. Sharma, H., Estep, M., Birerdinc, A., Afendy, A., Moazzez, A., Elariny, H., Goodman, Z., Chandhoke, V., Baranova, A., Younossi, Z.M., Expression of genes for microRNA-processing enzymes is altered in advanced non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 28:8 (2013), 1410–1415.
115. Sookoian, S., Puri, P., Castaño, G.O., Scian, R., Mirshahi, F., Sanyal, A.J., Pirola, C.J., Nonalcoholic Steatohepatitis is Associated with a State of Betaine-insufficiency. 2016, Liver International.
116. Sookoian, S., Rosselli, M.S., Gemma, C., Burgueno, A.L., Fernandez Gianotti, T., Castano, G.O., Pirola, C.J., Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 52:6 (2010), 1992–2000.
117. Sun, C., Fan, J.G., Qiao, L., Potential epigenetic mechanism in non-alcoholic Fatty liver disease. Int. J. Mol. Sci. 16:3 (2015), 5161–5179.
118. Sun, C., Huang, F., Liu, X., Xiao, X., Yang, M., Hu, G., Liu, H., Liao, L., miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int. J. Mol. Med. 35:3 (2015), 847–853.
119. Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., Zhai, Q., SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 6:4 (2007), 307–319.
120. Tacke, F., Luedde, T., Trautwein, C., Inflammatory pathways in liver homeostasis and liver injury. Clin. Rev. Allergy Immunol. 36:1 (2009), 4–12.
121. Tian, Y., Wong, V.W., Chan, H.L., Cheng, A.S., Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Semin. Cancer Biol. 23:6 Pt B (2013), 471–482.
122. Tomimaru, Y., Eguchi, H., Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Tanemura, M., Tomokuni, A., Takemasa, I., Umeshita, K., Kanto, T., Doki, Y., Mori, M., Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J. Hepatol. 56:1 (2012), 167–175.
123. Tryndyak, V.P., Han, T., Muskhelishvili, L., Fuscoe, J.C., Ross, S.A., Beland, F.A., Pogribny, I.P., Coupling global methylation and gene expression profiles reveal key pathophysiological events in liver injury induced by a methyl-deficient diet. Mol. Nutr. Food Res. 55:3 (2011), 411–418.
124. Tsai, W.C., Hsu, S.D., Hsu, C.S., Lai, T.C., Chen, S.J., Shen, R., Huang, Y., Chen, H.C., Lee, C.H., Tsai, T.F., Hsu, M.T., Wu, J.C., Huang, H.D., Shiao, M.S., Hsiao, M., Tsou, A.P., MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Investig. 122:8 (2012), 2884–2897.
125. Vickers, M.H., Early life nutrition, epigenetics and programming of later life disease. Nutrients 6:6 (2014), 2165–2178.
126. Vinciguerra, M., Sgroi, A., Veyrat-Durebex, C., Rubbia-Brandt, L., Buhler, L.H., Foti, M., Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 49:4 (2009), 1176–1184.
127. Wang, B., Li, W., Guo, K., Xiao, Y., Wang, Y., Fan, J., miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem. Biophys. Res. Commun. 421:1 (2012), 4–8.
128. Wang, H., Hou, L., Li, A., Duan, Y., Gao, H., Song, X., Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed. Res. Int., 2014, 2014, 864894.
129. Wang, L.J., Zhang, H.W., Zhou, J.Y., Liu, Y., Yang, Y., Chen, X.L., Zhu, C.H., Zheng, R.D., Ling, W.H., Zhu, H.L., Betaine attenuates hepatic steatosis by reducing methylation of the MTTP promoter and elevating genomic methylation in mice fed a high-fat diet. J. Nutr. Biochem. 25:3 (2014), 329–336.
130. Wei, Y., Rector, R.S., Thyfault, J.P., Ibdah, J.A., Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J. Gastroenterol., 14(2), 2008, 193.
131. Williams, M.D., Mitchell, G.M., MicroRNAs in insulin resistance and obesity. Exp. Diabetes Res., 2012, 2012, 484696.
132. Wu, H., Ng, R., Chen, X., Steer, C.J., Song, G., MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut, 2015.
133. Yan, X.L., Jia, Y.L., Chen, L., Zeng, Q., Zhou, J.N., Fu, C.J., Chen, H.X., Yuan, H.F., Li, Z.W., Shi, L., Xu, Y.C., Wang, J.X., Zhang, X.M., He, L.J., Zhai, C., Yue, W., Pei, X.T., Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology 57:6 (2013), 2274–2286.
134. Yeo, W., Chung, H.C., Chan, S.L., Wang, L.Z., Lim, R., Picus, J., Boyer, M., Mo, F.K., Koh, J., Rha, S.Y., Hui, E.P., Jeung, H.C., Roh, J.K., Yu, S.C., To, K.F., Tao, Q., Ma, B.B., Chan, A.W., Tong, J.H., Erlichman, C., Chan, A.T., Goh, B.C., Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. J. Clin. Oncol. 30:27 (2012), 3361–3367.
135. Yung, L.M., Leung, F.P., Yao, X., Chen, Z.Y., Huang, Y., Reactive oxygen species in vascular wall. Cardiovasc Hematol. Disord. Drug Targets 6:1 (2006), 1–19.
136. Zarfeshani, A., Ngo, S., Sheppard, A.M., MicroRNA expression relating to dietary-induced liver steatosis and NASH. J. Clin. Med. 4:11 (2015), 1938–1950.
137. Zeybel, M., Hardy, T., Robinson, S.M., Fox, C., Anstee, Q.M., Ness, T., Masson, S., Mathers, J.C., French, J., White, S., Mann, J., Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease. Clin. Epigenetics, 7, 2015, 25.
138. Zheng, L., Lv, G.C., Sheng, J., Yang, Y.D., Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J. Gastroenterol. Hepatol. 25:1 (2010), 156–163.
139. Zilberman, D., Henikoff, S., Genome-wide analysis of DNA methylation patterns. Development 134:22 (2007), 3959–3965.
140. Zimmer, V., Lammert, F., Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases. Best. Pract. Res. Clin. Gastroenterol. 25:2 (2011), 269–280.